It is believed to be transformed into two active inhibitors of acid secretion in the gastric parietal cells. Hepatic metabolism of lansoprazole is extensive. The two identified hepatic metabolites of lansoprazole have little antisecretory activity. Plasma elimination half-life, which is less than 2 hours, is not related to gastric antisecretory effect, which lasts more than 24 hours. Elimination half-life can be delayed as long as 7 hours in patients with hepatic impairment.
Elimination is believed to occur via biliary excretion.
Almost no unchanged lansoprazole is detected in urine after single-dose administration. Patients with impaired renal function showed no differences from healthy subjects. No differences were determined between male and female groups. There have been no studies of lansoprazole use in children. Although no studies have been done to determine if lansoprazole is similarly excreted into human milk, lansoprazole use is not recommended during breast-feeding.